當(dāng)前位置：   首頁(yè) > 需求大廳

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]

ID：嘻嘻嘻嘿嘿嘿，領(lǐng)取賞金；處理統(tǒng)計(jì)之后藥智網(wǎng)未收載的說(shuō)明書(shū)數(shù)量為36條，已收載的說(shuō)明書(shū)條數(shù)為43條，總的賞金=36*5+43*3=309   [更多]

求歐洲藥典關(guān)于B19病毒檢測(cè)方法的技術(shù)方法及要求，214頁(yè)原文。如有其它各國(guó)藥典標(biāo)準(zhǔn)對(duì)比則更好。   [更多]

需求名稱：歐洲藥典EP9.5的“Sutures, sterile non-absorbable”章節(jié)內(nèi)容 價(jià)格預(yù)算：300元 需求時(shí)間：請(qǐng)?jiān)?019年4月20號(hào)提交 交稿方式：請(qǐng)將文獻(xiàn)直接打包在藥智網(wǎng)交稿就可以了   [更多]

求購(gòu)“Fluorodopa (18F) (prepared by nucleophilic substitution) injection”《 EP9.7 》的藥典標(biāo)準(zhǔn)一份和親核取代法制備的“Radiopharmaceutical Preparations: Fluorodopa (18F) Injection”《 BP2019 》的藥典標(biāo)準(zhǔn)一份.   [更多]

求一份硝普鈉注射液的國(guó)內(nèi)外銷售數(shù)據(jù)，醫(yī)院和零售價(jià)格   [更多]

求仿制藥的國(guó)內(nèi)注冊(cè)流程   [更多]

公司需求幾篇藥品文獻(xiàn)資料。臨床應(yīng)用數(shù)據(jù)。具體產(chǎn)品私信我找到一篇50元   [更多]

需要地奧司明英國(guó)藥典的標(biāo)準(zhǔn)。 BP2017或者BP2018 或者2019都可以。   [更多]

求一份硝普鈉注射液的國(guó)內(nèi)外銷售數(shù)據(jù)，以及市場(chǎng)分析。   [更多]